press release

June 18, 2025

− R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – − Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 – CAMBRIDGE, Mass. (BUSINESS WIRE) Jun. 18, 2025 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and ...

press release

May 1, 2025

− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year Over Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR ...

news

March 25, 2025

2024 was a pivotal year for Alnylam, defined by strong commercial growth and outstanding progress within our pipeline and highlighted by the overwhelmingly positive data from the landmark HELIOS B study of vutrisiran for patients with ATTR amyloidosis with cardiomyopathy. The HELIOS B study met all ten of its primary and secondary endpoints and demonstrated an extraordinary impact in ...

press release

February 25, 2025

– Showcases multiple potentially transformative near and mid stage therapies in ATTR amyloidosis, Cardiovascular Disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next generation TTR silencer nucresiran in ATTR CM and hATTR PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to ...

capella

February 25, 2025

On February 25, 2025, we hosted an R&D Day event showcasing Alnylam's late stage clinical efforts, next wave programs, and platform advances. The event included presentations from Alnylam senior leaders, as well as a leading expert in Huntington's disease. To view the webcast, click here To view the presentation, click here Speakers: Yvonne Greenstreet, M.D. – Chief Executive Officer ...

webcast

February 14, 2025

press release

February 13, 2025

− Achieved Fourth Quarter and Full Year 2024 Global Net Product Revenues of $451 Million and $1,646 Million, Respectively, Representing 30% and 33% Growth Compared to Same Periods in 2023 – − Supplemental NDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Accepted by FDA, with March 23, 2025 PDUFA Date – − Reiterates Product Sales and Profitability Guidance ...

press release

November 17, 2024

− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months − − At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 − − Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing ...

press release

October 31, 2024

− Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year Over Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business – − Submitted Regulatory Applications in U.S. and EU for AMVUTTRA® (vutrisiran) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy – − Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of ...

press release

August 1, 2024

− Achieved Second Quarter 2024 Global Net Product Revenues of $410 Million, Representing 34% Year Over Year Growth Compared to Q2 2023, Driven by Continued Momentum from TTR Business, Which Delivered 37% Year Over Year Growth – − Reported Positive Topline Results from HELIOS B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both ...